Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | USP8 | P40818 | 2/20 | 0.47 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 2/20 | 0.43 |
| ▸ | TDP2 | O95551 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.43 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831967 | 0.88 | MAPT (0.43) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL19868500 | 0.79 | MAPT (0.53) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL29895822 | 0.76 | MAPT (0.59) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL28972029 | 0.76 | MAPT (0.59) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL21074805 | 0.75 | MAPT (0.48) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL19868491 | 0.73 | MAPT (0.47) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL21074799 | 0.72 | NPC1 (0.46) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL29895851 | 0.71 | USP8 (0.62) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL28972075 | 0.71 | USP8 (0.62) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL21074814 | 0.71 | ALDH1A1 (0.41) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3497083-B1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2022-01-19 | — | — | EP | disclosed |
| US-20190169136-A1 | Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-06-06 | — | — | US | disclosed |
| EP-3281940-A1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (FR) | 2018-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169136-A1 | Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease | NEDD8, USP8, USP18 | MAPT 3280/4885RAB9A 1292/4885ALDH1A1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.